Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

132 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Relationships between plasma insulin-like growth factor-I and insulin-like growth factor binding protein-3 and second breast cancer risk in a prevention trial of fenretinide.
Decensi A, Veronesi U, Miceli R, Johansson H, Mariani L, Camerini T, Di Mauro MG, Cavadini E, De Palo G, Costa A, Perloff M, Malone WF, Formelli F. Decensi A, et al. Among authors: perloff m. Clin Cancer Res. 2003 Oct 15;9(13):4722-9. Clin Cancer Res. 2003. PMID: 14581342 Clinical Trial.
Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer.
Veronesi U, De Palo G, Marubini E, Costa A, Formelli F, Mariani L, Decensi A, Camerini T, Del Turco MR, Di Mauro MG, Muraca MG, Del Vecchio M, Pinto C, D'Aiuto G, Boni C, Campa T, Magni A, Miceli R, Perloff M, Malone WF, Sporn MB. Veronesi U, et al. Among authors: perloff m. J Natl Cancer Inst. 1999 Nov 3;91(21):1847-56. doi: 10.1093/jnci/91.21.1847. J Natl Cancer Inst. 1999. PMID: 10547391 Clinical Trial.
Randomized trial of fenretinide in superficial bladder cancer using DNA flow cytometry as an intermediate end point.
Decensi A, Torrisi R, Bruno S, Costantini M, Curotto A, Nicolò G, Malcangi B, Baglietto L, Bruttini GP, Gatteschi B, Rondanina G, Varaldo M, Perloff M, Malone WF, Bruzzi P. Decensi A, et al. Among authors: perloff m. Cancer Epidemiol Biomarkers Prev. 2000 Oct;9(10):1071-8. Cancer Epidemiol Biomarkers Prev. 2000. PMID: 11045790 Clinical Trial.
Fenretinide: a prototype cancer prevention drug.
Malone W, Perloff M, Crowell J, Sigman C, Higley H. Malone W, et al. Among authors: perloff m. Expert Opin Investig Drugs. 2003 Nov;12(11):1829-42. doi: 10.1517/13543784.12.11.1829. Expert Opin Investig Drugs. 2003. PMID: 14585058 Review.
Tolerability of the synthetic retinoid Fenretinide (HPR).
Costa A, Malone W, Perloff M, Buranelli F, Campa T, Dossena G, Magni A, Pizzichetta M, Andreoli C, Del Vecchio M, et al. Costa A, et al. Among authors: perloff m. Eur J Cancer Clin Oncol. 1989 May;25(5):805-8. doi: 10.1016/0277-5379(89)90124-7. Eur J Cancer Clin Oncol. 1989. PMID: 2525470 Clinical Trial.
Transforming growth factor-alpha: a surrogate endpoint biomarker?
Beenken SW, Hockett R Jr, Grizzle W, Weiss HL, Pickens A, Perloff M, Malone WF, Bland KI. Beenken SW, et al. Among authors: perloff m. J Am Coll Surg. 2002 Aug;195(2):149-58. doi: 10.1016/s1072-7515(02)01219-x. J Am Coll Surg. 2002. PMID: 12168960 Clinical Trial.
Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis.
Brown VA, Patel KR, Viskaduraki M, Crowell JA, Perloff M, Booth TD, Vasilinin G, Sen A, Schinas AM, Piccirilli G, Brown K, Steward WP, Gescher AJ, Brenner DE. Brown VA, et al. Among authors: perloff m. Cancer Res. 2010 Nov 15;70(22):9003-11. doi: 10.1158/0008-5472.CAN-10-2364. Epub 2010 Oct 8. Cancer Res. 2010. PMID: 20935227 Free PMC article. Clinical Trial.
132 results